Page 224 - 2021_02-Haematologica-web

S. Nakahata et al.
AB
CD
E
Figure 4. Plasma sCADM1 levels are related to treatment efficacy in adult T-cell leukemia/lymphoma patients. (A) Soluble form of cell adhesion molecule 1 (sCADM1) concentrations in the plasma of 23 chronic-type, 13 lymphoma-type, and 43 acute-type adult T-cell leukemia/lymphoma (ATLL) patients who were previ- ously untreated and of 39 chronic-type, 18 lymphoma-type, and 7 acute-type ATLL patients who were previously treated with chemotherapy were measured by AlphaLISA. *P<0.05, ***P<0.001 (Mann-Whitney U test). The dot line indicates the 95th percentile of plasma sCADM1 in healthy subjects. Note that the pre-treat- ment and post-treatment samples were derived from different individuals. (B) Serum interleukin-2 receptor α (sIL2Rα) concentrations in the serum of 19 chronic- type, 12 lymphoma-type, and 43 acute-type ATLL patients who were previously untreated and of 32 chronic-type, 16 lymphoma-type, and six acute-type ATLL patients who were previously treated with chemotherapy. *P<0.05, ***P<0.001 (Mann-Whitney U test). The dot line indicates the upper limit of normal serum sIL2Rα. The same samples as Figure 4A were used. Fifteen cases with missing values on sIL2Rα (one lymphoma-type and four chronic-type in the pre-treatment group and one acute-type, two lymphoma-type, and seven chronic-type in the post-treatment group) were excluded. (C) Lactate dehydrogenase (LDH) concentrations in the serum of 18 chronic-type, nine lymphoma-type, and 40 acute-type ATLL patients who were previously untreated and of 15 chronic-type, seven lymphoma-type, and five acute-type ATLL patients who were previously treated with chemotherapy. *P<0.05 (Mann-Whitney U test). The dot line indicates the upper limit of normal serum LDH. The same samples as Figure 4A were used. Forty-nine cases with missing values on LDH (three acute-type, four lymphoma-type, and five chronic-type in the pre-treatment group and two acute-type, 11 lymphoma-type, and 24 chronic-type in the post-treatment group) were excluded. (D) Human T-cell leukemia virus type 1 (HTLV-1) proviral load (PVL) in 15 chronic-type, 11 lymphoma-type, and 35 acute-type ATLL patients who were previously untreated and in 39 chronic-type, 18 lym- phoma-type, and 7 acute-type ATLL patients who were previously treated with chemotherapy. **P<0.01 (Mann-Whitney U test). The same samples as Figure 4A were used. Eighteen cases with missing values on PVL (eight acute-type, two lymphoma-type, and eight chronic-type in the pre-treatment group) were excluded. (E) White blood cell counts (WBC) counts in 19 chronic-type, 11 lymphoma-type, and 43 acute-type ATLL patients who were previously untreated and in 33 chronic-type, 16 lymphoma-type, and 6 acute-type ATLL patients who were previously treated with chemotherapy. ***P<0.001 (Mann-Whitney U test). The dot line indicates the upper limit of normal for WBC counts. The same samples as Figure 4A were used. Thirteen cases with missing values on WBC counts (two lymphoma-type and four chron- ic-type in the pre-treatment group and one acute-type, two lymphoma-type, and four chronic-type in the post-treatment group) were excluded.
538
haematologica | 2021; 106(2)